Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)
Others
Ratios

Relay Therapeutics (RLAY) EPS (Weighted Average and Diluted): 2021-2024

Historic EPS (Weighted Average and Diluted) for Relay Therapeutics (RLAY) over the last 4 years, with Dec 2024 value amounting to -$2.36.

  • Relay Therapeutics' EPS (Weighted Average and Diluted) rose 31.75% to -$0.43 in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.72, marking a year-over-year increase of 34.10%. This contributed to the annual value of -$2.36 for FY2024, which is 15.41% up from last year.
  • According to the latest figures from FY2024, Relay Therapeutics' EPS (Weighted Average and Diluted) is -$2.36, which was up 15.41% from -$2.79 recorded in FY2023.
  • Relay Therapeutics' EPS (Weighted Average and Diluted)'s 5-year high stood at -$2.36 during FY2024, with a 5-year trough of -$3.82 in FY2021.
  • Moreover, its 3-year median value for EPS (Weighted Average and Diluted) was -$2.59 (2022), whereas its average is -$2.58.
  • Per our database at Business Quant, Relay Therapeutics' EPS (Weighted Average and Diluted) surged by 32.20% in 2022 and then declined by 7.72% in 2023.
  • Relay Therapeutics' EPS (Weighted Average and Diluted) (Yearly) stood at -$3.82 in 2021, then surged by 32.20% to -$2.59 in 2022, then declined by 7.72% to -$2.79 in 2023, then increased by 15.41% to -$2.36 in 2024.